Multi-omics Approach of Risk Stratification for Patients With de Novo Acute Myeloid Leukemia
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 入组人数
- 1,500
- 试验地点
- 1
- 主要终点
- Overall survival
研究概览
简要总结
The investigators will use machine learning to identify features on bone marrow smears and select features that are related to gene mutations, gene expression, or prognosis. The investigators will then use genome-wide transcriptomic profiling to investigate gene expression that is associated with patients' outcomes. The investigators will design a next-generation sequencing panel with unique molecular index and assess its feasibility and robustness in detecting measurable residual disease and optimize the panel/platform/bioinformatic pipeline. Finally, The investigators will use machine learning to integrate bone marrow smear features, gene mutations, gene expression, and measurable residual disease to construct a comprehensive risk assessment system that is based on multi-omics data. The investigators believe that such a platform will help physicians to design the most appropriate treatment strategies for individual patients, not only advancing the concept of precision medicine but also improving patients' prognoses.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with acute myeloid leukemia at the National Taiwan University Hospital
- •Ever enrolled in 201802021RINC、202109078RINB、201709072RINC
排除标准
- 未提供
结局指标
主要结局
Overall survival
时间窗: From date of diagnosis until the date of death from any cause, assessed up to 30 years
次要结局
未报告次要终点
研究者
National Taiwan University Clinical Trial Center
Assistant Professor and attending physician
National Taiwan University Hospital
